Enzyme linked to most prevalent mutational signatures in cancer cell lines

Enzyme linked to most prevalent mutational signatures in cancer cell lines
Using human cancer cell lines to investigate the origins of APOBEC3-associated mutagenesis. a, The experimental design used to track mutation acquisition in vitro over specific timeframes. The schematic was generated using BioRender. b, Profiles of APOBEC-associated signatures (sig.) extracted from SBSs identified across mutational catalogs of 5 stock cell lines and 251 parent and daughter clones. Mutational profiles are plotted as the percentage of genome-wide substitutions (y-axis) at cytosine or thymine bases classified into 96 possible trinucleotide sequence contexts (x-axis; Extended Data Fig. 4a). Subsequent deconvolution into COSMIC signatures revealed that SBS288A corresponds to COSMIC reference signature SBS2, SBS288B to SBS13 (termed SBS13a), whereas SBS288E represents a new version of COSMIC SBS13, which was termed SBS13b and quantified across samples in its extracted (rather than COSMIC) form. PCAWG, pan-cancer analysis of whole genomes; WGS, whole-genome sequencing. Credit: Nature (2022). DOI: 10.1038/s41586-022-04972-y

A team of researchers affiliated with several institutions in the U.S. and the U.K. has found a link between the APOBEC3A enzyme and the most prevalent mutational signatures in cancer cell lines. In their paper published in the journal Nature, the group describes removing APOBEC3 mutations from human cancer cell lines to learn more about possible clustered signatures.

Prior research has shown that the majority of cancer genomes have mutational signatures that can be associated with a family of enzymes known as APOBEC3. This work has suggested that these enzymes play a role in mutagenesis. Other prior work has suggested that the specific enzyme APOBEC3B is the most likely member of the family behind the ability of to mutate. In this new effort, the researchers have taken a closer look at another member of the family—APOBEC3A—and have found evidence that it is actually the enzyme most responsible for activation of mutations.

To learn more about possible APOBEC3 signatures, the researchers removed the mutations that gave rise to differences in the enzyme family, namely APOBEC3A and APOBEC3B, from cells making up in multiple human cell line samples. In all, they worked with 251 taken from patients with bladder, breast or lymphoma cancer.

The researchers then analyzed the samples to identify the signatures that were missing. They discovered that APOBEC3A had a stronger signature presence than APOBEC3B, suggesting that it is more likely the enzyme that is responsible for instigating cancerous mutations. They also note that their work is the first to show evidence of endogenous APOBEC enzymes as a main driver of mutational signatures in cancer cells.

The researchers note that their work did not rule out APOBEC3B as a contributor to mutational activity, however, because in some cells lines, deletion of APOBEC3B actually resulted in an increase in mutations. This finding suggested that the two enzymes may play different roles in different cells. They acknowledge that more work is required to discover whether such roles are mutually exclusive or if the enzymes work together. The researchers conclude that their work also backs up theories two decades in the making that surround the role played by the APOBEC3 enzyme family.

More information: Mia Petljak et al, Mechanisms of APOBEC3 mutagenesis in human cancer cells, Nature (2022). DOI: 10.1038/s41586-022-04972-y

Journal information: Nature

© 2022 Science X Network

Citation: Enzyme linked to most prevalent mutational signatures in cancer cell lines (2022, July 29) retrieved 11 December 2023 from https://medicalxpress.com/news/2022-07-enzyme-linked-prevalent-mutational-signatures.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

New class of drugs could stop cancers developing treatment resistance


Feedback to editors